Wild-type rabbitpox virus (RPV) produces red hemorrhagic pocks on the chorioallantoic membranes (CAMs) of embryonated chicken eggs. Like the crm4 (SPI-2) gene of cowpox virus, disruption of the RPV ps/hr gene results in a mutant which produces white pocks on the CAMs. An examination of the properties of the RPV(ps/hr) mutant in cell culture also reveals a significantly reduced host range, defined as the inability to form plaques, compared with wild-type virus. One of several cell types on which RPV(ps/hr) mutants fail to produce plaques is chicken embryo fibroblasts, cells which have been traditionally used to propagate spontaneously arising white pock mutants isolated from CAMs. The inability of the RPV(ps/hr) mutant to form plaques in chicken embryo fibroblasts correlates with a failure of a low multiplicity of infection to spread to neighboring cells and to form extracellular enveloped virus (EEV), although the formation and yields of infectious intracellular naked virus appear relatively normal. The gene product of the ps/hr gene, initially synthesized as a 45-kDa glycoprotein, is found as a component of EEV, but not intracellular naked virus, and as a smaller, secreted soluble protein of 35 kDa. Production of the secreted 35-kDa protein was found to be independent of any viral morphogenesis, suggesting two distinct pathways for release of the ps/hr gene product from the cell, i.e., as a component of the EEV particle and as a separately secreted glycoprotein.
The genes found within the single linear, double-stranded orthopoxvirus chromosome are generally organized into well-defined domains. A central internal conserved core of genes which encodes proteins essential for growth of the virus under all conditions can be delineated. Flanking this central core of genes and extending outward toward both the right and left termini are the regions of the viral chromosome which contain genes that are the most variable among individual viruses. Many of the genes located within the variable left and right terminal regions of these viruses, while nonessential, may be associated with host range in cell culture (28, 29, 40) . Some also have important roles in pathogenesis in vivo, i.e., acting to suppress the defense responses of the host organism to infection by the virus. One example is the crnA gene, originally described for cowpox virus (CPV) (30) (31) (32) . The crnA gene, which inhibits the interleukin-lp-converting enzyme, encodes a serpinlike protein which blocks the host inflammatory response when the chorioallantoic membranes (CAMs) of embryonated chicken eggs are subjected to infection with wild-type virus (32) . Other examples include a secreted, virus-encoded, interleukin-1 binding protein (1, 36, 38) , a gene which encodes a complement C4b binding protein that inhibits activation of both the classical and alternative complement pathways (16, 18, 19) , a tumor necrosis factor receptor homolog (15, 35) , and a protein which serves to alleviate the antiviral effects of interferon (2) .
One of the experimental systems exploited over the years for the study of poxviruses has been the color of lesions or pocks produced on the CAMs of embryonated eggs. Of the commonly studied orthopoxviruses, only wild-type CPV and * Corresponding author. rabbitpox virus (RPV) produce red or hemorrhagic pocks, whereas other members such as vaccinia virus produce pocks which are white and nonhemorrhagic. Although both CPV and RPV produce red hemorrhagic lesions, it is important to note that the lesions produced by CPV are somewhat more hemorrhagic than those produced by RPV. Spontaneous white pock variants of these two viruses arise at relatively high frequencies. At least some of the white pock mutants of CPV produce a white pock phenotype in response to loss of the crmA gene (30) . A histological examination of the white pocks in crmnA mutants suggested that the white, opaque nature of the pocks is due to an influx of inflammatory cells into the site of infection, consistent with the proposed role of the crmA gene in inhibiting hostmediated inflammation (13, 25) . We report here the identification of a second gene in RPV, which also controls pock color. This gene was first identified in the Lister strain of vaccinia virus as the ps/hr gene which when mutated led to loss of the ability of the virus to produce plaques on Vero cells (39) . In vaccinia virus WR, the gene is the B5R open reading frame (ORF). The protein product of the B5R ORF has been found as a component of extracellular enveloped virus (EEV) (10, 17) . Because the exact map position of the corresponding gene may differ in RPV, the gene is referred to in this communication as the ps/hr gene. We report here that an RPV mutant in the ps/hr gene, designated RPV(ps/ hr), produces distinctive white pocks on the CAM, shows a reduced host range, and fails to form plaques on a number of normally permissive cell lines, due at least in some cases to a failure to produce fully mature EEV. The protein product of the ps/hr gene, similar to that for the vaccinia virus homolog, is found as a 45-kDa component of RPV EEV (10, 17) and also as a smaller, secreted soluble protein of 35 Fenner and has been previously described in detail (5, 9, 20, 21) . Quail (QT-6) cells were the gift of C. and G. Moscovici of the University of Florida and were maintained in Opti-MEM medium (GIBCO) supplemented with 5% fetal bovine serum, 2 mM glutamine, 50 U of penicillin per ml, 50 ,ug of streptomycin per ml, 1 mM sodium pyruvate, and 0.1 mM minimal essential medium (MEM)-nonessential amino acids (GIBCO). Chicken embryo fibroblasts (CEFs) were prepared from 11-day-old embryos and maintained in medium 199 (GIBCO) in culture through nine passages. RK-13, CV-1, Rat-2, PK-15, and Vero cells were maintained in GIBCO MEM as described previously (41) .
Embryonated eggs from white Leghorn chickens were obtained from SPAFAS, Roanoke, Va., and incubated at 37.5°C. At 11 days postfertilization, the CAMs were inoculated with 200 p,l of phosphate-buffered saline (PBS) that contained either 50, 100, or 200 PFU of virus. After infection, the eggs were incubated at 37.5°C for 72 h, after which the CAMs were removed and rinsed in PBS for examination.
Construction of an RPV ps/hr gene disruption mutant. The Sal-HindIII fragment containing the ps/hr ORF was excised from the pMalCR-ps/hr plasmid and cloned into pBR322 to obtain the plasmid pBR322-ps/hr. The Ecogpt cassette (11) was excised from pBS-gpt-A (41) by EcoRI digestion, treated with the Klenow fragment of Escherichia coli DNA polymerase to obtain blunt ends, and inserted into the ps/hr ORF, using the EcoRV restriction site located 152 bp from the translation initiation codon (Fig. 1) . The resulting plasmid was called pBR322-ps/hr-gpt. The portion of the linearized plasmid pBR322-ps/hr-gpt containing the Ecogpt-disrupted ps/hr ORF was amplified by polymerase chain reaction (PCR), using the primers RM151 and RM152 and the plasmid as the DNA template. This PCR-generated DNA fragment was directly transfected into cells infected with wtRPV as described previously (41) . The RPV recombinants which contained a disrupted ps/hr gene were enriched by growth on CV-1 cells in selection medium which contained 2.5 p,g of mycophenolic acid per ml, 250 jig of xanthine per ml, and 15 p,g of hypoxanthine per ml. After enrichment, the virus was plated on RK-13 cells and transferred to nitrocellulose (plaque lifts) and individual plaques were identified after the plaque lifts were probed with radiolabeled Ecogpt DNA. Positive plaques were selected, and the purification procedure was repeated two more times. The purified viruses were amplified in RK-13 cells for further characterization.
Expression of the RPV ps/hr gene homolog in E. coli and preparation of antisera. The RPV ps/hr gene (ORF B5R of vaccinia virus WR) was amplified from RPV genomic DNA by using primers RM152, 5'-GGGjCGACATGAAAAC GATlTCCGT-3', and RM151, 5'-GGCAAGCITrATAT TCACGGTAGCA-3'. The primers were prepared on the basis of the published sequence of this gene from the Lister strain of vaccinia virus and are derived from the 5' and 3' sequences of the gene, respectively. Underlined regions contain added, noncoded SalI and HindIII sites used to clone the PCR product into the expression vector plasmid pMalCR-1 (New England Biolabs) to produce the plasmid pMalCR-ps/hr, which was then transformed into the TB1 strain of E. coli as described by New England Biolabs. After induction with isopropyl-f3-D-thiogalactopyranoside (IPTG), an abundant 84-kDa fusion protein resulting from the ps/hr gene product joined to the MalE protein (MalE-ps/hr) was expressed. The fusion protein was purified on an amylose resin column and was the antigen used for the immunization of two female New Zealand White rabbits for the generation of anti-ps/hr antiserum.
Western immunoblot analysis. Total wtRPV, EEV, and intracellular naked virus (INV) were purified as described by Payne (26) . The purified virus preparations, were dissociated in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer (12. 5 mM Tris-HCl [pH 6.8], 2% SDS, 100 mM dithiothreitol, 10% glycerol, and 0.01% bromophenol blue), boiled for 5 min, and loaded onto an SDS-6 to 15% gradient polyacrylamide gel. Proteins were transferred from the gel to nitrocellulose filters at 60 V for 5 h at 4°C in 25 mM Tris-HCl-192 mM glycine-20% methanol. The filter was blocked with 3% nonfat dry milk in TBS (10 mM Tris-HCl [pH 7.5], 150 mM NaCl), washed three times with TBS-0.05% Tween 20, and incubated overnight with a 1:250 dilution of the anti-ps/hr serum in TBS containing 3% bovine serum albumin (BSA). After three washes with TBS-0.05% Tween 20, the filter was incubated with a 1:1,000 dilution of alkaline phosphatase-conjugated goat anti-rabbit immunoglobulin G (Fisher-Biotech) in TBS-3% BSA for 2 h. The filter was washed three times in TBS-0.05% Tween 20 and developed with 100 mM Tris-HCl (pH 9.5)-100 mM NaCl-5 mM MgCl2 containing 330 ,ug of nitroblue tetrazolium per ml and 165 ,ug of 5-bromo-4-chloro-3-indolyl phosphate per ml.
Immunoprecipitations. Monolayers of CV-1 or RK-13 cells were infected at a multiplicity of infection (MOI) of 10. One hour after infection, the inoculum was removed and added to MEM supplemented with 1% fetal bovine serum, 2 mM glutamine, 50 U of penicillin per ml, 50 jxg of streptomycin per ml, 1 mM sodium pyruvate, and 0.1 mM MEM-nonessential amino acids. Proteins were radiolabeled for extended periods of time by removing the medium which was replaced by MEM containing 50 ,uCi of 35S-Translabel (ICN Biomedicals, Inc.) per ml and 1/10 the usual content of methionine and cysteine. Proteins were radiolabeled for short periods of time (30 min) by first removing the medium and washing the cells in medium lacking methionine and cysteine. The cells were then radiolabeled in the presence of 100 p,Ci of 35S-Translabel per ml in methionine-and cysteine-free medium. Where indicated, cells were incubated in the presence of tunicamycin (1 ,ug/ml) or rifampin (100 ,ug/ml) throughout the infection.
Radioactively labeled cells were washed twice with PBS and incubated for 1 h at 37°C in RIPA buffer (10 mM NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 10 mM Tris-HCI [pH 7.4], 2 mM methionine, and 10,000 Kallikrein inhibitor units of aprotinin per ml). The resulting cell lysate was clarified by centrifugation at 11,600 x g at 4°C for 15 min. A sample of the soluble cell extract containing 500,000 cpm was added to RIPA buffer containing 1% BSA and 0.02% NaN3 to a final volume of 100 or 200 ,ul. Antiserum (5 ,ul) was then added, and the mixture was incubated overnight at 4°C to allow formation of immunocomplexes. The immunocomplexes were collected by the addition of 30 A-Sepharose and Sepharose CILA B (Pharmacia) in PBS-0.02% NaN3, incubation at 4°C for 1 h, and then centrifugation at 11,600 x g for 30 s. The immunoprecipitates were washed four times with RIPA buffer-1% BSA. The bound proteins were resolved in an SDS-6 to 15% acrylamide gradient gel and detected by fluorography (6) .
Removal of EEV from clarified supematants was achieved by centrifugation at 11,600 x g for 30 min. The EEVdepleted supernatants were supplemented to contain NaCl, Nonidet P-40, deoxycholate, SDS, methionine, BSA, and Tris-HCl to the concentrations present in RIPA buffer and immunoprecipitated as described above.
CsCl density gradient resolution of radiolabeled INV and EEV. Confluent monolayers (5 x 106 cells per 60-mmdiameter dish) were infected at an MOI of 10 at 37°C. At 2 h postinfection, [methyl-3H]thymidine was added to a final concentration of 10 ,uCi/ml. At 24 or 48 h postinfection, the extracellular medium was removed and centrifuged for 10 min at 1,000 x g for clarification and then at 100,000 x g for 40 min to collect the EEV. The EEV was suspended in 2 ml of distilled water for analysis on CsCl gradients.
To obtain INV and cell-associated enveloped virus (CEV), cells were harvested in PBS and lysed in distilled water with a Dounce homogenizer. Nuclei were removed by centrifugation at 1,000 x g for 10 min. The supernatants were sonicated briefly and layered onto a 4.0-ml 36% sucrose pad and centrifuged at 31,000 x g for 90 min. The viral pellet was resuspended in 2 ml of distilled water for analysis on CsCl gradients.
The 2-ml virus samples, derived from either the medium or the cells, were layered onto a discontinuous CsCl gradient (26) and centrifuged at 175,000 x g for 90 min. Dropwise fractions (0.5 ml) were collected from the bottoms of the tubes, and the radioactivity in each fraction was quantitated.
RESULTS
Construction of RPV(ps/hr) mutants lacking a functional ps/hr gene. The ps/hr gene of wtRPV was inactivated by insertion of an Ecogpt cassette consisting of the E. coli Ecogpt gene driven by the vaccinia virus p7.5 promoter (11) . Details of the construction are in the Materials and Methods. The site for insertion of the Ecogpt cassette is an EcoRV restriction site 152 bp downstream of the putative translation initiating ATG codon (Fig. 1A ). This construction not only disrupts the ORF but creates a stop codon in the junction between the N-terminal region of the ps/hr ORF and the inserted selectable marker and ensures that a polypeptide of only 50 amino acids would be expressed in the recombinant virus. The Ecogpt insertion site is also conveniently located near an EcoRI restriction site which facilitates confirmation of the predicted construction (Fig. 1A) . When wtRPV is digested with EcoRI, the single site within the ps/hr gene generates fragments of 13 and 7.5 kb containing ps/hr gene sequences. Insertion of the Ecogpt cassette, which is devoid of EcoRI sites, into the EcoRV site adds approximately 2.5 kb to the 13-kb fragment (Fig. 1A ). This prediction is confirmed when wtRPV and RPV(ps/hr) DNAs digested with EcoRI are probed with a sample of radiolabeled ps/hr gene DNA (Fig. 1B) .
Behavior of the RPV(ps/hr) mutants on the CAM. The sequence of the ps/hr gene shows significant homology to several complement control proteins (10, 17, 37, 39) . It has been shown that depletion of complement can alter the pock J. VIROL. morphology of the infected CAM (22) . We therefore examined the behavior of the ps/hr mutant of RPV on the CAM. As can be seen from the data in Fig. 2 , whereas wtRPV forms the expected typical red hemorrhagic pocks, the RPV(ps/hr) mutant yields small, distinctive, white nonhemorrhagic pocks ( Fig. 2A) . A closer examination of the pocks shows that although a significant degree of vasodilation occurs within the wtRPV pocks, the immediate region of the pocks remains generally clear except for some extravasated red cells. The general morphology of the RPV(ps/hr) pocks is cloudy and opaque and shows little if any extravasated red cells and no vasodilation (Fig. 2B) .
The ps/hr gene regulates the host range of the virus and is required for the formation of plaques in CEFs. The original description of the ps/hr gene mutants of the Lister strain of vaccinia virus suggested that the mutants not only formed smaller plaques in general but failed to produce plaques at all on Vero cells (39) . We have examined the ability of the RPV(ps/hr) mutant to form plaques on a variety of cell lines. The mutant not only failed to produce plaques on Vero cells as expected (39) but also failed to produce plaques on pig kidney (PK-15) cells, CEFs, or quail (QT-6) cells (Fig. 3 ). In the rest of the cell lines tested (CV-1, Rat-2, and RK-13), the mutant plaques were always smaller than those of wtRPV. The exceptions are the avian cell lines (CEF and QT-6) in which the mutant fails to produce plaques even though wtRPV forms large, easily visible plaques.
The conversion from red to white pock phenotype of RPV has been exploited for years for the isolation of host range mutants, because about half of the spontaneous white pock mutants which appear on the CAM exhibit a restricted host range. In all these earlier studies, however, the accepted permissive cell line for growth of these white pock mutants has been CEFs (12, 14, 33) . The RPV(ps/hr) mutant, then, represents the first class of white pock host range mutants which fails to produce plaques in these two avian cell lines and within CEFs in particular (Fig. 3) . Since it has been assumed that any white pock variant identified on the CAM would grow in CEFs, there are probably more genes, other than the crmA and ps/hr genes, which when mutated can generate white pocks.
Growth properties of the RPV(ps/hr) mutant. The role of the ps/hr gene in growth and spread of the virus was evaluated after low-multiplicity infections of various cell lines. Cells (RK-13, Vero, or CEFs) were infected at an MOI of 0.001, and total virus production was monitored over a period of up to 4 days postinfection. The results are shown in Fig. 4 . The times of maximum yields of both wild-type and mutant virus are similar in RK-13 cells. Surprisingly, the kinetics and yield of both wild-type and mutant virus are quite similar in Vero cells, even though the mutant fails to produce plaques in this cell line. The total yield of virus compared with that of RK-13 cells is in either case, however, significantly less. The most striking difference between wildtype and mutant virus is on CEFs, in which the mutant virus spread is severely delayed and the yields are considerably less compared with that of wild-type virus.
Disruption of the ps/hr gene of RPV leads to impaired production of EEV in CEFs. The inability of the vaccinia virus or RPV(ps/hr) mutants to produce plaques in certain cell lines does not necessarily indicate failure of viral growth. Indeed, despite the inability to form plaques (Fig. 3 ) and the profound effects on virus production in CEFs (Fig.  4) , the patterns of viral protein synthesis in RPV(ps/hr)-infected cells are similar to those observed for wtRPV (19a) . There are at least two possible explanations for the behavior of the RPV(ps/hr) mutant. The first is that noninfectious virus might be formed. Alternatively, in nonpermissive cells, there may be a block in viral morphogenesis.
We examined permissive (RK-13) and nonpermissive (CEF) cells for the ability to form viral particles. The CEFs were chosen for examination because they are clearly the most defective in virus production (Fig. 4) (26) .
RPV and the RPV(ps/hr) mutant form nearly identical levels of both INV (Fig. 5A) and EEV (Fig. 5C ) in permissive RK-13 cells. The second major peak of virus isolated from within permissive cells (Fig. 5A ) is thought to represent CEV. The RPV(ps/hr) mutant forms somewhat less CEV than does wtRPV in RK-13 cells.
In nonpermissive CEFs, the RPV(ps/hr) mutant forms roughly half the levels of INV of wtRPV and very little CEV (Fig. 5B) . Virtually no EEV is formed by the RPV(ps/hr) mutant compared with wtRPV (Fig. 5D) We have presented data to suggest that the RPV(ps/hr) mutant exhibits a reduced host range and fails to produce plaques on a number of cell lines (Fig. 3) (Fig. 7) .
The ps/hr protein shares a significant degree of homology
RK-13
Cv-1 with the vaccinia virus C4b complement control protein homolog (VCP), a secreted 28-kDa protein (10, 16, 18, 19) . The failure to specifically immunoprecipitate a 28-kDa protein with the anti-ps/hr serum from wtRPV-infected cells or supernates (19a) and the fact that the VCP gene is deleted in RPp,hr23 (5) attest to the fact that the anti-ps/hr serum is specific for the ps/hr gene product and does not cross-react with the related VCP.
The ps/hr protein is present in RPV EEV particles. Previous work has shown that mutations in genes encoding proteins found in the EEV particle can block EEV but not INV production (3, 8, 10, 34) . The fact that mutations in the ps/hr gene prevent production of EEV in only certain cell lines raised the question of whether the protein is a component of the RPV EEV particle. This hypothesis was tested by immunoblot analysis of purified INV and EEV using antips/hr serum (Fig. 8) . As can be seen, a 45-kDa ps/hr protein is specifically detected in EEV with anti-ps/hr serum but not with preimmune serum. This protein was not detectable in INV. While it is clear from this study that under normal conditions the ps/hr protein is specifically associated with EEV, it is equally clear that the protein is not an absolute requirement either for EEV formation or for EEV particle integrity in some cell lines (Fig. 5) .
We have also consistently noticed a diffuse immunopositive band of around 84 kDa. While the identity of this band is not known, it is not the result of spurious cross-reaction of the anti-ps/hr serum with the virus-encoded HA of this molecular size, because wtRPV is an HA-negative virus due to a mutation in the HA gene (7) . These results would be consistent with the formation of ps/hr dimers, as has been proposed previously (10) .
A smaller 35-kDa form of the ps/hr protein is secreted into the medium by wtRPV-infected cells. An examination of the predicted amino acid sequence of the ps/hr protein indicates two highly hydrophobic regions located at both the N-and C-terminal extremes of the molecule (10, 17, 39) . These structural elements would be consistent with a signal sequence and membrane anchor, respectively. Despite the presence of a potential membrane anchor, we asked whether the ps/hr protein, like the VCP protein with which it shares some sequence similarities, might be secreted. In order to examine this question, we analyzed supernatants of RPV-, CPV-, and vaccinia virus WR-infected cells, from which EEV had been removed by centrifugation, for the presence of the ps/hr protein. The results are shown in Fig. 9 labeled infected cells. However, when the label was removed after the 30-min labeling period and the cells were incubated another 2.5 h in medium that contained an excess of unlabeled methionine and cysteine (chased), even though the 45-kDa ps/hr protein could still be observed within the cells, the smaller 35-kDa ps/hr protein was now clearly visible in the supernatant fraction depleted of EEV (Fig. 10) . These results suggest that the 35-kDa form of the ps/hr protein is derived by cleavage of the preformed 45-kDa ps/hr protein rather by direct synthesis. Indeed, a careful examination of the samples of immunoprecipitated cells, which were further incubated and chased after labeling, shows the appearance of a small peptide near the bottom of the gel which could represent the smaller cleavage product of the 45-kDa protein.
Formation of the 35-kDa ps/hr gene product is independent of EEV formation. The experiment shown in Fig. 10 suggests that the 35-kDa ps/hr gene product is derived from a 45-kDa protein by cleavage. We next chose to address in more detail the relationship of the secretion of the 35-kDa ps/hr protein and the formation of EEV which contains the 45-kDa form of the ps/hr protein. This was achieved by a more extended kinetic analysis of the formation of the cell-associated 45-kDa ps/hr protein, the appearance of the 45-kDa protein in EEV, and the 35-kDa secreted form of the protein. The cells were first labeled for a 30-min period at 9 h postinfection as for the experiment shown in Fig. 10 (Fig. 11) . The results shown in Fig. 11 indicate that the 35-kDa form of the protein appears more rapidly than the 45-kDa form associated with EEV. These results suggest that the smaller 35-kDa protein can be formed and secreted independently of EEV formation and hence is probably not sion of red to white pocks results from a generalized failure of these mutants, unlike the behavior of wild-type virus, to prevent -the influx of immune cells into the pock which restricts the host inflammatory response (13, 24, 25, 32) . Here we show that a mutation in the ps/hr gene of RPV likewise leads to the production of white pocks ( Fig. 2A) . Whether the white pocks produced by the ps/hr mutant results from a similar mechanism awaits further experimentation. Nevertheless, our results indicate that production of the wild-type red pock may depend on genes other than crmA.
The genome of CPV is considerably larger than that of RPV, and it is quite possible that the genes required for production of red pocks on the CAMs may differ in these two viruses. Although both CPV and RPV form red hemorrhagic pocks on the CAM, those of RPV are less intense. Mutations in the crmA (SPI-2) gene of either RPV or CPV generate white pocks. We have also shown that CPV has a ps/hr gene and that disruption of this gene in CPV generates a CPV mutant which like RPV produces white pocks (38a). However, mutations in the SPI-1 gene, present in both RPV and CPV, which shares significant homology with the cnnA gene, yield distinctive white pocks only in RPV (la).
The white pocks of the RPV(ps/hr) mutant, like cnn A mutants of RPV and CPV, on close inspection appear cloudy and opaque (Fig. 2B) . It is interesting to note that wtRPV red pocks show a typical extravasation of red cells and vasodilation, neither of which occur in RPV(ps/hr) white pocks (Fig. 2B) . A detailed histological analysis of the white pocks produced by the RPV(ps/hr) mutant is in progress.
Potential clues for the role of ps/hr protein in determining pock morphology come from the sequence and the biochemical characteristics of the protein. The ps/hr protein shares homology with complement control proteins such as factor H and the C4b binding protein (10, 39) . Complement may play an important role in limiting viral infection, because treatment of infected eggs with cobra venom factor to deplete complement leads to the formation of much more diffuse pocks on the CAM (22, 23) . Depletion of complement in the chicken leads to enhanced growth of attenuated strains of fowlpox virus and inhibits inflammation (22) . Complement may act through mediation of infected cell lysis, through neutralization of virus particles, or by mediating the inflammatory response through release of anaphylatoxins (chemoattractants) such as C5a or C3a. The virus-encoded C4b binding protein (VCP), which shares significant sequence homology with the ps/hr protein, is secreted and has been shown to inhibit both the classical and alternative complement pathways in vitro (16, 18, 19) . However, no complement-inhibitory activity, as measured by inhibition of hemolysis (18) , has been detected in supernatant fractions lacking the VCP protein, suggesting that the ps/hr protein may function differently than the VCP protein. Perhaps the ps/hr protein acts to protect the infected cell and/or the EEV particle, localization sites for the ps/hr protein ( Fig. 8 and 11 ) (10, 17) , from complement-mediated lysis or neutralization.
The second striking property of the RPV(ps/hr) mutant is a reduced host range ( Fig. 3 and 4 virus which then moves to the plasma membrane (27) . As this virus exits the cell, a layer of membrane is lost, creating a double-membrane virus, part of which is cell associated (CEV) and some of which is released (EEV). The major defect in the RPV(ps/hr) mutant is a failure to produce either CEV or EEV in nonpermissive cells such as CEFs. The level of INV, however, though somewhat diminished, remains substantial (Fig. 5) . These results add further credence to the work of others that indicates that INV plays little if any role in the spread of the virus but that CEV and EEV must form in order for the virus to produce plaques in cell culture (3, 4, 8, 34) . Although fully permissive on RK-13 cells, the RPV(ps/hr) mutants form smaller plaques (Fig. 3) . It is possible that the smaller plaques in RK-13 cells reflect the lower yields of CEV by the mutant, because INV and EEV levels are equivalent in wild-type and mutant viruses. The host range nature of the mutation and the presence of the ps/hr protein within EEV particles of RPV (Fig. 8) and vaccinia virus (10, 17) suggest that, in certain cells, the ps/hr gene product is essential for the assembly and/or secretion of EEV.
It is also clear from comparing the data shown in Fig. 3  and 4 that the failure a priori of a virus to form plaques does not necessarily indicate a failure to grow or spread. This is exemplified by contrasting the behavior of the RPV(ps/hr) mutant on Vero cells and CEFs. We confirmed the initial studies (39) that ps/hr gene mutants fail to form plaques on Vero cells (Fig. 3 ). Yet, low-multiplicity infections of Vero cells by the RPV(ps/hr) mutant (Fig. 4) show a rate of growth and spread similar to that of wtRPV. Since wtRPV plaques produced on Vero cells are quite small, it is easy to imagine that even small negative effects on growth rates (CEV and EEV levels) might result in a failure to produce visible plaques on Vero cells. The situation in CEFs, however, is quite different where by contrast the plaques formed by wtRPV are large. In CEFs, little if any detectable spread or growth of virus is revealed by the low-multiplicity infections, suggesting a true host range phenotype with a much more complete inhibition of the virus.
Although synthesis of the ps/hr gene mRNA has been reported both early and late in vaccinia virus-infected cells (10) , the protein product of the ps/hr gene appears to be expressed late in RPV-infected cells (Fig. 6) as a 45-kDa tunicamycin-sensitive glycoprotein (Fig. 11) . Later in infection, some of the 45-kDa protein is found extracellularly as a component of released EEV (Fig. 8 and 11 ) and hence depends on the formation of EEV to be released from the cell. No association of the protein with INV was found.
The secretion of a portion of the ps/hr protein as a smaller 35-kDa molecule does not depend on virus assembly (Fig.  12) . These results suggest that a second morphogenesisindependent secretory pathway operates for movement of that portion of the ps/hr protein destined to be cleaved to Fig. 2A .
ADDENDUM
After the manuscript was submitted, a cell line-dependent role of the ps/hr gene (B5R ORF homolog) in EEV production was reported by Engelstad and Smith (10a).
